Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandy Srinivas

Showing results (121-130 of 153) with videos related to

Pageof 16
Sort By:
Cancer Medicine|April 18, 2017
Characterizing the outcomes of metastatic papillary renal cell carcinomaJohn Connor Wells, Frede Donskov, Anna P Fraccon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabMatthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable NeoplasmTorgrim Tandstad, Christian K Kollmannsberger, Bruce J Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2012
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaToni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2010
NCCN clinical practice guidelines in oncology: prostate cancerJames Mohler, Robert R Bahnson, Barry Boston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerPeter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.
Lancet (London, England)|March 9, 2016
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological CorrelationsLaurence Albiges, A Ari Hakimi, Wanling Xie, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 17, 2013
Prostate cancer, version 1.2014James L Mohler, Philip W Kantoff, Andrew J Armstrong, et al.
Pageof 16

Showing results (121-130 of 153) with videos related to

Sort By:
Pageof 16
Cancer Medicine|April 18, 2017
Characterizing the outcomes of metastatic papillary renal cell carcinomaJohn Connor Wells, Frede Donskov, Anna P Fraccon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabMatthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable NeoplasmTorgrim Tandstad, Christian K Kollmannsberger, Bruce J Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2012
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaToni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2010
NCCN clinical practice guidelines in oncology: prostate cancerJames Mohler, Robert R Bahnson, Barry Boston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerPeter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.
Lancet (London, England)|March 9, 2016
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological CorrelationsLaurence Albiges, A Ari Hakimi, Wanling Xie, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 17, 2013
Prostate cancer, version 1.2014James L Mohler, Philip W Kantoff, Andrew J Armstrong, et al.
Pageof 16